Table of Content

1 INTRODUCTION 21
1.1 OBJECTIVES OF THE STUDY 21
1.2 MARKET DEFINITION 21
1.3 MARKET SCOPE 22
1.3.1 MARKETS COVERED 22
1.3.2 YEARS CONSIDERED FOR THE STUDY 23
1.4 CURRENCY USED FOR THE STUDY 23
1.5 MAJOR MARKET STAKEHOLDERS 23

2 RESEARCH METHODOLOGY 24
2.1 RESEARCH DATA 24
2.1.1 SECONDARY DATA 25
2.1.1.1 Secondary sources 26
2.1.2 PRIMARY DATA 27
2.2 MARKET ESTIMATION METHODOLOGY 28
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 29
2.2.2 PROCEDURE-BASED MARKET ESTIMATION 29
2.2.3 PRIMARY RESEARCH VALIDATION 30
2.3 DATA TRIANGULATION 31
2.4 RESEARCH ASSUMPTIONS 32
2.5 RESEARCH LIMITATIONS 32

3 EXECUTIVE SUMMARY 33

4 PREMIUM INSIGHTS 37
4.1 HLA TYPING FOR TRANSPLANTS MARKET OVERVIEW 37
4.2 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY 38
4.3 REGIONAL ANALYSIS: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION 39
4.4 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2019 40
4.5 REGIONAL ANALYSIS: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE 41
4.6 HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY 42

5 MARKET OVERVIEW 43
5.1 INTRODUCTION 43
5.2 MARKET DYNAMICS 43
5.2.1 KEY MARKET DRIVERS 44
5.2.1.1 Increasing number of transplant procedures 44
5.2.1.2 Technological advancements in the field of HLA typing 44
5.2.1.3 Increasing public-private funding for target research activities 45
5.2.2 KEY MARKET RESTRAINTS 46
5.2.2.1 High costs of molecular tests used for HLA typing procedures 46
5.2.2.2 Limited reimbursements for target procedures 47
5.2.3 KEY MARKET OPPORTUNITIES 48
5.2.3.1 Rising adoption of cross-matching and chimerism testing during
pre- & post-transplantation 48
5.2.3.2 Technological shift from non-molecular serological assays to gene-based HLA profiling 48
5.2.3.3 Increasing public awareness about organ donation and transplantation across emerging countries 48
5.2.4 KEY MARKET CHALLENGES 49
5.2.4.1 Significant gap between the number of organ donors and organs required annually 49

6 HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE 50
6.1 INTRODUCTION 51
6.2 REAGENTS & CONSUMABLES 51
6.2.1 INCREASING PATIENT EMPHASIS ON EFFECTIVE PATIENT PROFILING DURING ORGAN TRANSPLANTATION TO DRIVE MARKET GROWTH 51
6.3 INSTRUMENTS 52
6.3.1 INCREASING PATIENT AWARENESS ABOUT THE BENEFITS OFFERED
BY GENOME-BASED PROFILING WILL SUPPORT MARKET GROWTH 52
6.4 SOFTWARE & SERVICES 53
6.4.1 RISING DEMAND FOR INNOVATIVE HLA TYPING SOFTWARE DURING
THE DETECTION OF SPECIFIC ALLELES IS SUPPORTING MARKET GROWTH 53

7 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY 55
7.1 INTRODUCTION 56
7.2 MOLECULAR ASSAY TECHNOLOGIES 56
7.2.1 PCR-BASED MOLECULAR ASSAYS 58
7.2.1.1 Sequence-specific oligonucleotide-PCR 61
7.2.1.1.1 Growing awareness about the benefits offered by SSO-PCR among medical professionals to drive market growth 61
7.2.1.2 Sequence-specific primer-PCR 62
7.2.1.2.1 Growing public-private investments for research activities to support market growth 62
7.2.1.3 Real-time PCR 63
7.2.1.3.1 High cost of real-time PCR and procedural complexity to hamper market growth 63
7.2.1.4 Other PCR-based molecular assays 64
7.2.2 SEQUENCING-BASED MOLECULAR ASSAYS 65
7.2.2.1 Sanger sequencing 67
7.2.2.1.1 Growing demand for high-throughput DNA sequencers to drive market growth 67
_
7.2.2.2 Next-generation sequencing 68
7.2.2.2.1 Expansion in the application horizons of NGS in the field of tissue typing to support market growth 68
7.2.2.3 Other sequencing-based molecular assays 69
7.3 NON-MOLECULAR ASSAY TECHNOLOGIES 70
7.3.1 REPLACEMENT OF NON-MOLECULAR ASSAY TECHNIQUES WITH DNA-BASED HLA TYPING PROCEDURES IS EXPECTED TO HAMPER MARKET GROWTH 70

8 HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION 73
8.1 INTRODUCTION 74
8.2 DIAGNOSTIC APPLICATIONS 74
8.2.1 ANTIBODY SCREENING 75
8.2.1.1 Rising number of recipients for transplant procedures to drive
market growth 75
8.2.2 CHIMERISM MONITORING 76
8.2.2.1 Rising trend of personalized transplant medicine for effective post-procedural clinical risk management to drive market growth 76
8.2.3 OTHER APPLICATIONS 77
8.3 RESEARCH APPLICATIONS 78
8.3.1 INCREASING IDENTIFICATION OF NEW GENES & BIOMARKERS IN DONOR-RECIPIENT CROSS MATCH WILL DRIVE THE MARKET GROWTH 78

9 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER 79
9.1 INTRODUCTION 80
9.2 INDEPENDENT REFERENCE LABORATORIES 80
9.2.1 INCREASING NUMBER OF PREVENTIVE GENOMIC CLINICS TO DRIVE
MARKET GROWTH 80
9.3 HOSPITALS & TRANSPLANT CENTERS 81
9.3.1 HEALTHCARE CONSOLIDATION AND ESTABLISHMENT OF NEW HOSPITALS TO SUPPORT MARKET GROWTH 81
9.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES 82
9.4.1 GROWING AWARENESS ABOUT THE RESEARCH APPLICATIONS IN TRANSPLANT REJECTION MONITORING TO DRIVE MARKET GROWTH 82

10 HLA TYPING FOR TRANSPLANTS MARKET, BY REGION 84
10.1 INTRODUCTION 85
10.2 NORTH AMERICA 85
10.2.1 US 89
10.2.1.1 Ongoing technological advancements in the field of HLA typing to drive market growth in the US 89
10.2.2 CANADA 91
10.2.2.1 Growing availability of HLA typing products to support market growth in Canada 91
_
10.3 EUROPE 92
10.3.1 GERMANY 96
10.3.1.1 Germany accounted for the largest share of the European market 96
10.3.2 UK 98
10.3.2.1 Rising number of transplantation procedures to drive market growth in the UK 98
10.3.3 FRANCE 100
10.3.3.1 Adoption of molecular diagnostic techniques for donor-recipient compatibility testing is increasing in France 100
10.3.4 ITALY 102
10.3.4.1 Sluggish growth in the Italian healthcare sector in the last few years to restrain market growth 102
10.3.5 SPAIN 103
10.3.5.1 Rising number of solid organ transplantation procedures to drive market growth in Spain 103
10.3.6 REST OF EUROPE 105
10.4 ASIA PACIFIC 106
10.4.1 JAPAN 110
10.4.1.1 Significant growth in chronic disease prevalence to support market growth in Japan 110
10.4.2 CHINA 112
10.4.2.1 Healthcare infrastructure improvements to support market growth
in China 112
10.4.3 INDIA 113
10.4.3.1 Increasing number of transplantation procedures to drive market growth in India 113
10.4.4 AUSTRALIA 115
10.4.4.1 Rising number of solid organ transplantation procedures to support market growth in Australia 115
10.4.5 SOUTH KOREA 117
10.4.5.1 Government initiatives to introduce medical coverage for transplantation to support market growth in South Korea 117
10.4.6 REST OF ASIA PACIFIC 118
10.5 LATIN AMERICA 119
10.5.1 BRAZIL 122
10.5.1.1 Brazil accounted for the largest share of the LATAM market 122
10.5.2 MEXICO 124
10.5.2.1 Rising medical tourism to support market growth in Mexico 124
10.5.3 REST OF LATIN AMERICA 125
10.6 MIDDLE EAST AND AFRICA 127
_
11 COMPETITIVE LANDSCAPE 130
11.1 OVERVIEW 130
11.2 MARKET SHARE ANALYSIS 131
11.3 COMPETITIVE SCENARIO 132
11.3.1 KEY PRODUCT LAUNCHES AND APPROVALS 132
11.3.2 KEY AGREEMENTS AND COLLABORATIONS 132
11.3.3 KEY ACQUISITIONS 133
11.3.4 KEY EXPANSIONS 133
11.4 COMPETITIVE LEADERSHIP MAPPING 133
11.4.1 VISIONARY LEADERS 134
11.4.2 INNOVATORS 134
11.4.3 DYNAMIC DIFFERENTIATORS 134
11.4.4 EMERGING COMPANIES 134
12 COMPANY PROFILES 136
(Business overview, Products offered, Recent developments, MNM view)*
12.1 THERMO FISHER SCIENTIFIC 136
12.2 F. HOFFMAN-LA ROCHE LIMITED 141
12.3 QIAGEN 143
12.4 IMMUCOR 148
12.5 ABBOTT LABORATORIES INC. 151
12.6 CAREDX, INC. 153
12.7 ILLUMINA 156
12.8 BIO-RAD LABORATORIES 160
12.9 ALPHA BIOTECH, LTD. 162
12.10 GENDX 163
12.11 LUMINEX 165
12.12 BIOFORTUNA 167
12.13 OMIXON 169
12.14 CREATIVE BIOLABS 171
12.15 TBG DIAGNOSTICS LIMITED 172
12.16 OTHER COMPANIES 175
12.16.1 BAG HEALTHCARE 175
12.16.2 TAKARA BIO 176
12.16.3 HISTOGENETICS LLC 177
12.16.4 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 178
12.16.5 HANSA BIOPHARMA AB 179
*Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.
_
13 APPENDIX 180
13.1 DISCUSSION GUIDE 180
13.3 AVAILABLE CUSTOMIZATIONS 191
13.4 RELATED REPORTS 192
13.5 AUTHOR DETAILS 193



List of Figures



FIGURE 1 RESEARCH DESIGN 24
FIGURE 2 BREAKDOWN OF PRIMARIES: GLOBAL HLA TYPING FOR TRANSPLANTS MARKET 27
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 28
FIGURE 4 MARKET SIZE ESTIMATION: HLA TYPING FOR TRANSPLANTS MARKET 30
FIGURE 5 DATA TRIANGULATION METHODOLOGY 31
FIGURE 6 HLA TYPING FOR TRANSPLANTS MARKET SHARE, BY PRODUCT & SERVICE 2019 VS. 2025 33
FIGURE 7 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY 2019 VS. 2025 (USD MILLION) 34
FIGURE 8 HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION 2019 VS. 2025 (USD MILLION) 34
FIGURE 9 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER 2019 VS. 2025 (USD MILLION) 35
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE HLA TYPING FOR TRANSPLANTS MARKET 36
FIGURE 11 INCREASING NUMBER OF TRANSPLANTATION PROCEDURES TO DRIVE MARKET GROWTH DURING THE FORECAST PERIOD 37
FIGURE 12 PCR-BASED MOLECULAR ASSAYS TO DOMINATE THE MARKET DURING
THE FORECAST PERIOD 38
FIGURE 13 ANTIBODY SCREENING AND CHIMERISM MONITORING SEGMENTS TO WITNESS HIGH GROWTH IN THE ASIA PACIFIC MARKET 39
FIGURE 14 INDEPENDENT REFERENCE LABORATORIES ARE THE LARGEST END USERS IN
THE APAC MARKET 40
FIGURE 15 NORTH AMERICA IS ESTIMATED TO BE THE LARGEST MARKET FOR ALL PRODUCT & SERVICE SEGMENTS IN THE HLA TYPING FOR TRANSPLANTS MARKET IN 2019 41
FIGURE 16 MARKET IN CHINA AND INDIA TO WITNESS THE HIGHEST GROWTH DURING
THE FORECAST PERIOD 42
FIGURE 17 HLA TYPING FOR TRANSPLANTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 43
FIGURE 18 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET SNAPSHOT 86
FIGURE 19 SOLID ORGAN TRANSPLANTATIONS PERFORMED IN THE US, 2015–2019 89
FIGURE 20 SOLID ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN CANADA 2015–2018 91
FIGURE 21 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET SNAPSHOT 93
FIGURE 22 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET SNAPSHOT 107
FIGURE 23 NUMBER OF SOLID ORGAN TRANSPLANTATION PROCEDURES PERFORMED
IN JAPAN, 2015–2018 110
FIGURE 24 PRODUCT LAUNCHES AND ENHANCEMENTS WERE THE KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM 2016 TO 2019 130
FIGURE 25 THERMO FISHER SCIENTIFIC DOMINATED THE GLOBAL HLA TYPING FOR TRANSPLANTS MARKET IN 2019 131
FIGURE 26 HLA TYPING FOR TRANSPLANTS MARKET: GLOBAL COMPETITIVE LEADERSHIP MAPPING, 2019 135
FIGURE 27 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2018) 136
FIGURE 28 F. HOFFMAN-LA ROCHE LIMITED: COMPANY SNAPSHOT (2018) 141
FIGURE 29 QIAGEN: COMPANY SNAPSHOT (2018) 143
FIGURE 30 IMMUCOR: COMPANY SNAPSHOT (2016) 148
FIGURE 31 ABBOTT LABORATORIES INC.: COMPANY SNAPSHOT (2018) 151
FIGURE 32 CAREDX: COMPANY SNAPSHOT (2018) 153
FIGURE 33 ILLUMINA: COMPANY SNAPSHOT (2018) 156
FIGURE 34 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2018) 160
FIGURE 35 LUMINEX: COMPANY SNAPSHOT (2018) 165
FIGURE 36 TBG DIAGNOSTICS LIMITED: COMPANY SNAPSHOT (2018) 172

 

List of Tables



TABLE 1 PUBLIC-PRIVATE INVESTMENTS AND RESEARCH GRANTS FOR THE DEVELOPMENT OF HLA TYPING PRODUCTS FOR TRANSPLANT PROCEDURES, 2015–2018 45
TABLE 2 COST OF ASSAYS FOR MAJOR NGS/PCR-BASED GENOMIC TESTS IN EUROPE
(AS OF 2017) 46
TABLE 3 APPLICABLE CODES FOR HLA TYPING 47
TABLE 4 HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE 2017–2025 (USD MILLION) 51
TABLE 5 REAGENTS & CONSUMABLES MARKET, BY REGION, 2017–2025 (USD MILLION) 52
TABLE 6 INSTRUMENTS MARKET, BY REGION, 2017–2025 (USD MILLION) 53
TABLE 7 SOFTWARE & SERVICES MARKET, BY REGION, 2017–2025 (USD MILLION) 54
TABLE 8 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY 2017–2025 (USD MILLION) 56
TABLE 9 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE 2017–2025 (USD MILLION) 57
TABLE 10 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY PRODUCT 2017–2025 (USD MILLION) 57
TABLE 11 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY APPLICATION 2017–2025 (USD MILLION) 57
TABLE 12 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY END USER 2017–2025 (USD MILLION) 58
TABLE 13 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY REGION 2017–2025 (USD MILLION) 58
TABLE 14 PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION) 59
TABLE 15 PCR-BASED MOLECULAR ASSAYS MARKET, BY PRODUCT 2017–2025 (USD MILLION) 59
TABLE 16 PCR-BASED MOLECULAR ASSAYS MARKET, BY APPLICATION 2017–2025 (USD MILLION) 60
TABLE 17 PCR-BASED MOLECULAR ASSAYS MARKET, BY END USER 2017–2025 (USD MILLION) 60
TABLE 18 PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION 2017–2025 (USD MILLION) 61
TABLE 19 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR MARKET, BY REGION 2017–2025 (USD MILLION) 62
TABLE 20 SEQUENCE-SPECIFIC PRIMER-PCR MARKET, BY REGION 2017–2025 (USD MILLION) 63
TABLE 21 REAL-TIME PCR MARKET, BY REGION, 2017–2025 (USD MILLION) 64
TABLE 22 OTHER PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION 2017–2025 (USD MILLION) 64
TABLE 23 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 65
TABLE 24 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY PRODUCT 2017–2025 (USD MILLION) 66
TABLE 25 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY APPLICATION 2017–2025 (USD MILLION) 66
TABLE 26 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY END USER 2017–2025 (USD MILLION) 67
TABLE 27 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION 2017–2025 (USD MILLION) 67
TABLE 28 SANGER SEQUENCING MARKET, BY REGION, 2017–2025 (USD MILLION) 68
TABLE 29 NEXT-GENERATION SEQUENCING MARKET, BY REGION 2017–2025 (USD MILLION) 69
TABLE 30 OTHER SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION 2017–2025 (USD MILLION) 69
TABLE 31 NON-MOLECULAR ASSAY TECHNOLOGIES MARKET, BY PRODUCT 2017–2025 (USD MILLION) 70
TABLE 32 NON-MOLECULAR ASSAY TECHNOLOGIES MARKET, BY APPLICATION 2017–2025 (USD MILLION) 71
TABLE 33 NON-MOLECULAR ASSAY TECHNOLOGIES MARKET, BY END USER 2017–2025 (USD MILLION) 71
TABLE 34 NON-MOLECULAR ASSAY TECHNOLOGIES MARKET, BY REGION 2017–2025 (USD MILLION) 72
TABLE 35 HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION 2017–2025 (USD MILLION) 74
TABLE 36 DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2017–2025 (USD MILLION) 75
TABLE 37 DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2017–2025 (USD MILLION) 75
TABLE 38 ANTIBODY SCREENING MARKET, BY REGION, 2017–2025 (USD MILLION) 76
TABLE 39 CHIMERISM MONITORING MARKET, BY REGION, 2017–2025 (USD MILLION) 77
TABLE 40 OTHER DIAGNOSTIC APPLICATIONS MARKET, BY REGION 2017–2025 (USD MILLION) 77
TABLE 41 RESEARCH APPLICATIONS MARKET, BY REGION, 2017–2025 (USD MILLION) 78
TABLE 42 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER 2017–2025 (USD MILLION) 80
TABLE 43 INDEPENDENT REFERENCE LABORATORIES MARKET, BY REGION 2017–2025 (USD MILLION) 81
TABLE 44 HOSPITALS & TRANSPLANT CENTERS MARKET, BY REGION 2017–2025 (USD MILLION) 82
TABLE 45 RESEARCH LABORATORIES & ACADEMIC INSTITUTES MARKET, BY REGION 2017–2025 (USD MILLION) 83
TABLE 46 HLA TYPING FOR TRANSPLANTS MARKET, BY REGION, 2017–2025 (USD MILLION) 85
TABLE 47 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY 2017–2025 (USD MILLION) 86
TABLE 48 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 87
TABLE 49 NORTH AMERICA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 87
TABLE 50 NORTH AMERICA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET BY TYPE, 2017–2025 (USD MILLION) 87
TABLE 51 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET BY PRODUCT & SERVICE, 2017–2025 (USD MILLION) 88
TABLE 52 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 88
TABLE 53 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER 2017–2025 (USD MILLION) 88
TABLE 54 US: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY 2017–2025 (USD MILLION) 90
TABLE 55 US: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 90
TABLE 56 US: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 90
TABLE 57 CANADA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY 2017–2025 (USD MILLION) 91
TABLE 58 CANADA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 92
TABLE 59 CANADA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 92
TABLE 60 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY 2017–2025 (USD MILLION) 94
TABLE 61 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY 2017–2025 (USD MILLION) 94
TABLE 62 EUROPE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 94
TABLE 63 EUROPE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 95
TABLE 64 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2017–2025 (USD MILLION) 95
TABLE 65 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION 2017–2025 (USD MILLION) 95
TABLE 66 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER 2017–2025 (USD MILLION) 96
TABLE 67 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN GERMANY, 2015 VS. 2018 96
TABLE 68 GERMANY: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY 2017–2025 (USD MILLION) 97
TABLE 69 GERMANY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 97
TABLE 70 GERMANY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 97
TABLE 71 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN THE UK 2015 VS. 2018 98
TABLE 72 UK: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY 2017–2025 (USD MILLION) 99
TABLE 73 UK: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 99
TABLE 74 UK: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 99
TABLE 75 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN FRANCE 2015 VS. 2018 100
TABLE 76 FRANCE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY 2017–2025 (USD MILLION) 101
TABLE 77 FRANCE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 101
TABLE 78 FRANCE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 101
TABLE 79 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN ITALY 2015 VS. 2018 102
TABLE 80 ITALY: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY 2017–2025 (USD MILLION) 102
TABLE 81 ITALY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 103
TABLE 82 ITALY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 103
TABLE 83 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN SPAIN 2015 VS. 2018 104
TABLE 84 SPAIN: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY 2017–2025 (USD MILLION) 104
TABLE 85 SPAIN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 104
TABLE 86 SPAIN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 105
TABLE 87 ROE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY 2017–2025 (USD MILLION) 105
TABLE 88 ROE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 106
TABLE 89 ROE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 106
TABLE 90 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY 2017–2025 (USD MILLION) 108
TABLE 91 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY 2017–2025 (USD MILLION) 108
TABLE 92 ASIA PACIFIC: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 108
TABLE 93 ASIA PACIFIC: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION) 109
TABLE 94 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2017–2025 (USD MILLION) 109
TABLE 95 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION 2017–2025 (USD MILLION) 109
TABLE 96 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER 2017–2025 (USD MILLION) 110
TABLE 97 JAPAN: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY 2017–2025 (USD MILLION) 111
TABLE 98 JAPAN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 111
TABLE 99 JAPAN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 111
TABLE 100 NUMBER OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN CHINA, 2013 VS. 2015 112
TABLE 101 CHINA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY 2017–2025 (USD MILLION) 112
TABLE 102 CHINA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 113
TABLE 103 CHINA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 113
TABLE 104 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN INDIA 2015 VS. 2018 114
TABLE 105 INDIA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY 2017–2025 (USD MILLION) 114
TABLE 106 INDIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 114
TABLE 107 INDIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 115
TABLE 108 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN AUSTRALIA, 2015 VS. 2018 115
TABLE 109 AUSTRALIA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY 2017–2025 (USD MILLION) 116
TABLE 110 AUSTRALIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 116
TABLE 111 AUSTRALIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 116
TABLE 112 SOUTH KOREA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 117
TABLE 113 SOUTH KOREA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 117
TABLE 114 SOUTH KOREA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION) 118
TABLE 115 ROAPAC: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY 2017–2025 (USD MILLION) 118
TABLE 116 ROAPAC: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 119
TABLE 117 ROAPAC: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 119
TABLE 118 LATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY 2017–2025 (USD MILLION) 120
TABLE 119 LATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY 2017–2025 (USD MILLION) 120
TABLE 120 LATAM: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 120
TABLE 121 LATAM: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 121
TABLE 122 LATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE 2017–2025 (USD MILLION) 121
TABLE 123 LATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION 2017–2025 (USD MILLION) 121
TABLE 124 LATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER 2017–2025 (USD MILLION) 122
TABLE 125 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN BRAZIL 2015 VS. 2018 122
TABLE 126 BRAZIL: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY 2017–2025 (USD MILLION) 123
TABLE 127 BRAZIL: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 123
TABLE 128 BRAZIL: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 123
TABLE 129 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN MEXICO 2015 VS. 2018 124
TABLE 130 MEXICO: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY 2017–2025 (USD MILLION) 124
TABLE 131 MEXICO: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 125
TABLE 132 MEXICO: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 125
TABLE 133 ROLATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY 2017–2025 (USD MILLION) 126
TABLE 134 ROLATAM: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 126
TABLE 135 ROLATAM: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 126
TABLE 136 MEA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY 2017–2025 (USD MILLION) 127
TABLE 137 MEA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 127
TABLE 138 MEA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE 2017–2025 (USD MILLION) 128
TABLE 139 MEA: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE 2017–2025 (USD MILLION) 128
TABLE 140 MEA: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION 2017–2025 (USD MILLION) 128
TABLE 141 MEA: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER 2017–2025 (USD MILLION) 129